Immunome, Inc. announced that their cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in pseudovirus testing. IMM-BCP-01 is currently in Phase 1b clinical testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5 and BA.2. IMM-BCP-01 is a three-antibody cocktail with each antibody having a different mechanism of action. IMM20190 binds to a composite epitope involving the receptor binding ridge and an area adjacent to the receptor binding loop preventing binding to ACE2.

IMM20184 and IMM20253 neutralized live BA.2 Omicron variant in vitro testing as well as pseudoviruses corresponding to the BA.2.12.1 and BA.4/.5 subvariants. In particular, IMM20253 neutralized the virus through an ACE2-independent mechanism that differs from the neutralization mechanisms used by current or past antibodies approved for clinical use. Data recently published in Science Immunology provides a mechanistic basis for how IMM20253 binding, which is conserved across all variants to date including Omicron and its sub-lineages, neutralized SARS-CoV-2. The investigational work for IMM-BCP-01 was funded by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in collaboration with the Defense Health Agency (DHA).